Viral Vectors & Plasmid DNA Manufacturing Market Size Record US$ 10.6 Bn by 2030

SHARE THIS ARTICLE

The global Viral Vectors & Plasmid DNA Manufacturing market size is expected to be worth around US$ 10.6 billion by 2030, according to a new report by Vision Research Reports.

The global Viral Vectors & Plasmid DNA Manufacturing market size was valued at US$ 3.2 billion in 2020 and is anticipated to grow at a CAGR of 20.8% during forecast period 2021 to 2030.

Get Sample Copy of This Report (Including TOC, List of Tables & Figures, and Chart)@ https://www.visionresearchreports.com/report/sample/38494

Viral Vectors & Plasmid DNA Manufacturing Market Size 2020 to 2030

Growth Factors

Advent of advanced therapies including gene therapy that employs the use of various viral and non-viral vectors has paved a way for the treatment of several heritable and acquired diseases that previously lacked effective treatment modalities. Post the approval of Novartis’s Zolgensma, drug developers have begun considering these new areas of treatment as a sustainable business model. Thus, the speculated accelerating investment is expected to drive the growth.

Current production methods for viral vectors are considered tedious, as they are only applicable for scale-out but not for scale-up. Development of a proprietary CAP-GT technology-based cell suspension system by CEVEC Pharmaceuticals GmbH has effectively addressed the challenge of scaling-up by allowing easy handling and improved efficiency of cells. 

Report Coverage

Report Scope Details
Market Size USD 10.6 Billion by 2030
Growth Rate CAGR of 20.8% From 2021 to 2030
Base Year 2020
Historic Data 2017 to 2020
Forecast Period 2021 to 2030
Segments Covered Type, Workflow, Application, End-use, Disease
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Mentioned Novasep, Aldevron, MerckWaismanBiomanufacturing, Creative Biogene,The Cell and Gene Therapy Catapult,Cobra Biologics,uniQure N.V.,Addgene,FUJIFILM Holdings Corporation,Oxford Biomedicaplc,Takara Bio Inc. 

 

Vector Type Insights

Targeted delivery, efficient transduction, and controlled gene expression are some of the key factors taken into consideration while manufacturing vectors. Viral vectors are increasingly being employed in the ongoing clinical trials owing to their efficiency in gene delivery. Out of all the viral vectors, adenovirus and retrovirus are most commonly used within research settings across the globe.

Workflow Insights

The growing necessity of vectors to meet the rising demand for robust therapies has pronounced the need for optimization of upstream processing and downstream processing workflows. Virus preparation methods at small-scale involve steps that are difficult to scale-up and are often considered tedious.

Aplication Insights

Antisense and RNAi, gene therapies are the leading application of viral and plasmid vector in terms of revenue share. Small interfering RNAs (siRNAs) are currently considered significant tools for post-transcriptional gene silencing during a genetic analysis of cells. The presence of pipeline products is expected to boost growth of this segment over the forecast period.

Furthermore, the emergence of retroviral vectors as a viable solution for addressing the low transfection efficiency-related drawbacks of plasmid-based systems is one of the key development in antisense and RNAi production. Growing usage of AAV vectors for delivery of siRNA in mammalian cells is driving revenue in this segment.

End-use Insights

Pharmaceutical and biotechnology companies accounted for the largest share in the viral vectors & plasmid DNA manufacturing market in 2019. This can be attributed to the continuous introduction of advanced therapies coupled with a subsequent increase in the number of gene therapy-based discovery programs by companies. The number of biotech companies employing vectors for therapeutics production continues to increase over the period of time.

Disease Insights

Viral vectors are being studied for both preventive and therapeutic applications in cancer. Viral vector-based immunization with anticancer antigens or delivery of toxic or anticancer genes are some key areas or research that have shown steady progress in recent times. Furthermore, recent approvals of lentiviral vector-based CAR-T cell therapies for Acute Lymphoblastic Leukemia (ALL) and large B cell lymphoma have attracted considerable attention from key end-users. This has resulted in significant proliferation in the cancer-based pipeline projects on advanced therapies.

Regional Insights

Recent FDA approval of advanced therapies such as Kymriah (tisagenlecleucel) and Yescarta is one of the key factors contributing to the largest revenue share of the U.S. market. These approvals have resulted in an increase in the number of companies operating in this area in U.S. In 2020, an estimated 391 gene therapy companies were operating in the U.S. By September 2019, around 100 more companies including big pharma companies entered the market. 

Key Players

  • Novasep
  • Aldevron
  • MerckWaismanBiomanufacturing
  • Creative Biogene
  • The Cell and Gene Therapy Catapult
  • Cobra Biologics
  • uniQure N.V.
  • Addgene
  • FUJIFILM Holdings Corporation
  • Oxford Biomedicaplc
  • Takara Bio Inc. 

Market Segmentation

 By Vector Type Outlook 

  • Adenovirus
  • Retrovirus
  • Plasmid DNA
  • AAV
  • Lentivirus
  • Others

By Workflow Outlook 

  • Upstream Processing
    • Vector Amplification & Expansion
    • Vector Recovery/Harvesting
  • Downstream Processing
    • Purification
    • Fill-finish

By Application Outlook 

  • Antisense & RNAi
  • Gene Therapy
  • Cell Therapy
  • Vaccinology

By End-use Outlook 

  • Pharmaceutical and Biopharmaceutical Companies
  • Research Institutes

By Disease Outlook

  • Cancer
  • Genetic Disorders
  • Infectious Diseases
  • Others

By Regional Outlook 

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
  • Asia Pacific
    • China
    • Japan
  • Latin America
    • Brazil
  • Middle East & Africa
    • South Africa

Table of Contents

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. Market Dynamics Analysis and Trends

5.1. Market Dynamics

5.1.1. Market Drivers

5.1.2. Market Restraints

5.1.3. Market Opportunities

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining power of suppliers

5.2.2. Bargaining power of buyers

5.2.3. Threat of substitute

5.2.4. Threat of new entrants

5.2.5. Degree of competition

Chapter 6. Competitive Landscape

6.1.1. Company Market Share/Positioning Analysis

6.1.2. Key Strategies Adopted by Players

6.1.3. Vendor Landscape

6.1.3.1. List of Suppliers

6.1.3.2. List of Buyers

Chapter 7. Global Viral Vectors & Plasmid DNA Manufacturing Market, By Vector Type

7.1. Viral Vectors & Plasmid DNA Manufacturing Market, by Vector Type, 2021-2030

7.1.1. Adenovirus

7.1.1.1. Market Revenue and Forecast (2017-2030)

7.1.2. Plasmid DNA

7.1.2.1. Market Revenue and Forecast (2017-2030)

7.1.3. Lentivirus

7.1.3.1. Market Revenue and Forecast (2017-2030)

7.1.4. Retrovirus

7.1.4.1. Market Revenue and Forecast (2017-2030)

7.1.5. AAV

7.1.5.1. Market Revenue and Forecast (2017-2030)

7.1.6. Others

7.1.6.1. Market Revenue and Forecast (2017-2030)

Chapter 8. Global Viral Vectors & Plasmid DNA Manufacturing Market, By Application Type

8.1. Viral Vectors & Plasmid DNA Manufacturing Market, by Application Type, 2021-2030

8.1.1. Gene Therapy

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Antisense &RNAi

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Cell Therapy

8.1.3.1. Market Revenue and Forecast (2017-2030)

8.1.4. Vaccinology

8.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Viral Vectors & Plasmid DNA Manufacturing Market, By Workflow Type

9.1. Viral Vectors & Plasmid DNA Manufacturing Market, by Workflow Type, 2021-2030

9.1.1. Upstream Processing (Vector Recovery/Harvesting, Vector Amplification & Expansion)

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Downstream Processing (Fill-finish, Purification)

9.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Viral Vectors & Plasmid DNA Manufacturing Market, By End-User Type

10.1. Viral Vectors & Plasmid DNA Manufacturing Market, by End-User Type, 2021-2030

10.1.1. Biopharmaceutical and Pharmaceutical Companies

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Research Institutes

10.1.2.1. Market Revenue and Forecast (2017-2030)

 

Chapter 11. Global Viral Vectors & Plasmid DNA Manufacturing Market, By Disease

 

11.1. Viral Vectors & Plasmid DNA Manufacturing Market, by Disease, 2021-2030

11.1.1. Genetic Disorders

11.1.1.1. Market Revenue and Forecast (2017-2030)

11.1.2. Cancer

11.1.2.1. Market Revenue and Forecast (2017-2030)

11.1.3. Infectious Diseases

11.1.3.1. Market Revenue and Forecast (2017-2030)

11.1.4. Others

11.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Viral Vectors & Plasmid DNA Manufacturing Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Vector (2017-2030)

12.1.2. Market Revenue and Forecast, by Application (2017-2030)

12.1.3. Market Revenue and Forecast, by Workflow (2017-2030)

12.1.4. Market Revenue and Forecast, by End-User (2017-2030)

12.1.5. Market Revenue and Forecast, by Disease (2017-2030)

12.1.6. U.S.

12.1.6.1. Market Revenue and Forecast, by Vector (2017-2030)

12.1.6.2. Market Revenue and Forecast, by Application (2017-2030)

12.1.6.3. Market Revenue and Forecast, by Workflow (2017-2030)

12.1.6.4. Market Revenue and Forecast, by End-User (2017-2030)

12.1.7. Market Revenue and Forecast, by Disease (2017-2030)

12.1.8. Rest of North America

12.1.8.1. Market Revenue and Forecast, by Vector (2017-2030)

12.1.8.2. Market Revenue and Forecast, by Application (2017-2030)

12.1.8.3. Market Revenue and Forecast, by Workflow (2017-2030)

12.1.8.4. Market Revenue and Forecast, by End-User (2017-2030)

12.1.9. Market Revenue and Forecast, by Disease (2017-2030)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Vector (2017-2030)

12.2.2. Market Revenue and Forecast, by Application (2017-2030)

12.2.3. Market Revenue and Forecast, by Workflow (2017-2030)

12.2.4. Market Revenue and Forecast, by End-User (2017-2030)

12.2.5. Market Revenue and Forecast, by Disease (2017-2030)

12.2.6. UK

12.2.6.1. Market Revenue and Forecast, by Vector (2017-2030)

12.2.6.2. Market Revenue and Forecast, by Application (2017-2030)

12.2.6.3. Market Revenue and Forecast, by Workflow (2017-2030)

12.2.7. Market Revenue and Forecast, by End-User (2017-2030)

12.2.8. Market Revenue and Forecast, by Disease (2017-2030)

12.2.8.1. Market Revenue and Forecast, by Raw Material (2017-2030)

12.2.9. Germany

12.2.9.1. Market Revenue and Forecast, by Vector (2017-2030)

12.2.9.2. Market Revenue and Forecast, by Application (2017-2030)

12.2.9.3. Market Revenue and Forecast, by Workflow (2017-2030)

12.2.10. Market Revenue and Forecast, by End-User (2017-2030)

12.2.11. Market Revenue and Forecast, by Disease (2017-2030)

12.2.12. France

12.2.12.1. Market Revenue and Forecast, by Vector (2017-2030)

12.2.12.2. Market Revenue and Forecast, by Application (2017-2030)

12.2.12.3. Market Revenue and Forecast, by Workflow (2017-2030)

12.2.12.4. Market Revenue and Forecast, by End-User (2017-2030)

12.2.13. Market Revenue and Forecast, by Disease (2017-2030)

12.2.14. Rest of Europe

12.2.14.1. Market Revenue and Forecast, by Vector (2017-2030)

12.2.14.2. Market Revenue and Forecast, by Application (2017-2030)

12.2.14.3. Market Revenue and Forecast, by Workflow (2017-2030)

12.2.14.4. Market Revenue and Forecast, by End-User (2017-2030)

12.2.15. Market Revenue and Forecast, by Disease (2017-2030)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Vector (2017-2030)

12.3.2. Market Revenue and Forecast, by Application (2017-2030)

12.3.3. Market Revenue and Forecast, by Workflow (2017-2030)

12.3.4. Market Revenue and Forecast, by End-User (2017-2030)

12.3.5. Market Revenue and Forecast, by Disease (2017-2030)

12.3.6. India

12.3.6.1. Market Revenue and Forecast, by Vector (2017-2030)

12.3.6.2. Market Revenue and Forecast, by Application (2017-2030)

12.3.6.3. Market Revenue and Forecast, by Workflow (2017-2030)

12.3.6.4. Market Revenue and Forecast, by End-User (2017-2030)

12.3.7. Market Revenue and Forecast, by Disease (2017-2030)

12.3.8. China

12.3.8.1. Market Revenue and Forecast, by Vector (2017-2030)

12.3.8.2. Market Revenue and Forecast, by Application (2017-2030)

12.3.8.3. Market Revenue and Forecast, by Workflow (2017-2030)

12.3.8.4. Market Revenue and Forecast, by End-User (2017-2030)

12.3.9. Market Revenue and Forecast, by Disease (2017-2030)

12.3.10. Japan

12.3.10.1. Market Revenue and Forecast, by Vector (2017-2030)

12.3.10.2. Market Revenue and Forecast, by Application (2017-2030)

12.3.10.3. Market Revenue and Forecast, by Workflow (2017-2030)

12.3.10.4. Market Revenue and Forecast, by End-User (2017-2030)

12.3.10.5. Market Revenue and Forecast, by Disease (2017-2030)

12.3.11. Rest of APAC

12.3.11.1. Market Revenue and Forecast, by Vector (2017-2030)

12.3.11.2. Market Revenue and Forecast, by Application (2017-2030)

12.3.11.3. Market Revenue and Forecast, by Workflow (2017-2030)

12.3.11.4. Market Revenue and Forecast, by End-User (2017-2030)

12.3.11.5. Market Revenue and Forecast, by Disease (2017-2030)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Vector (2017-2030)

12.4.2. Market Revenue and Forecast, by Application (2017-2030)

12.4.3. Market Revenue and Forecast, by Workflow (2017-2030)

12.4.4. Market Revenue and Forecast, by End-User (2017-2030)

12.4.5. Market Revenue and Forecast, by Disease (2017-2030)

12.4.6. GCC

12.4.6.1. Market Revenue and Forecast, by Vector (2017-2030)

12.4.6.2. Market Revenue and Forecast, by Application (2017-2030)

12.4.6.3. Market Revenue and Forecast, by Workflow (2017-2030)

12.4.6.4. Market Revenue and Forecast, by End-User (2017-2030)

12.4.7. Market Revenue and Forecast, by Disease (2017-2030)

12.4.8. North Africa

12.4.8.1. Market Revenue and Forecast, by Vector (2017-2030)

12.4.8.2. Market Revenue and Forecast, by Application (2017-2030)

12.4.8.3. Market Revenue and Forecast, by Workflow (2017-2030)

12.4.8.4. Market Revenue and Forecast, by End-User (2017-2030)

12.4.9. Market Revenue and Forecast, by Disease (2017-2030)

12.4.10. South Africa

12.4.10.1. Market Revenue and Forecast, by Vector (2017-2030)

12.4.10.2. Market Revenue and Forecast, by Application (2017-2030)

12.4.10.3. Market Revenue and Forecast, by Workflow (2017-2030)

12.4.10.4. Market Revenue and Forecast, by End-User (2017-2030)

12.4.10.5. Market Revenue and Forecast, by Disease (2017-2030)

12.4.11. Rest of MEA

12.4.11.1. Market Revenue and Forecast, by Vector (2017-2030)

12.4.11.2. Market Revenue and Forecast, by Application (2017-2030)

12.4.11.3. Market Revenue and Forecast, by Workflow (2017-2030)

12.4.11.4. Market Revenue and Forecast, by End-User (2017-2030)

12.4.11.5. Market Revenue and Forecast, by Disease (2017-2030)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Vector (2017-2030)

12.5.2. Market Revenue and Forecast, by Application (2017-2030)

12.5.3. Market Revenue and Forecast, by Workflow (2017-2030)

12.5.4. Market Revenue and Forecast, by End-User (2017-2030)

12.5.5. Market Revenue and Forecast, by Disease (2017-2030)

12.5.6. Brazil

12.5.6.1. Market Revenue and Forecast, by Vector (2017-2030)

12.5.6.2. Market Revenue and Forecast, by Application (2017-2030)

12.5.6.3. Market Revenue and Forecast, by Workflow (2017-2030)

12.5.6.4. Market Revenue and Forecast, by End-User (2017-2030)

12.5.7. Market Revenue and Forecast, by Disease (2017-2030)

12.5.8. Rest of LATAM

12.5.8.1. Market Revenue and Forecast, by Vector (2017-2030)

12.5.8.2. Market Revenue and Forecast, by Application (2017-2030)

12.5.8.3. Market Revenue and Forecast, by Workflow (2017-2030)

12.5.8.4. Market Revenue and Forecast, by End-User (2017-2030)

12.5.8.5. Market Revenue and Forecast, by Disease (2017-2030)

Chapter 13. Company Profiles

13.1. Novasep

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Aldevron

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Merck Waisman Biomanufacturing

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Creative Biogene

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. The Cell and Gene Therapy Catapult

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Cobra Biologics

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. uniQure N.V.

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Addgene

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. FUJIFILM Holdings Corporation

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Oxford Biomedicaplc

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

13.11. Takara Bio Inc.

13.11.1. Company Overview

13.11.2. Product Offerings

13.11.3. Financial Performance

13.11.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

The study objectives of this report are:

  • To analyze and study the global market capacity, production, value, consumption, status (2017-2020) and forecast (2021-2030);
  • Focuses on the key manufacturers, to study the capacity, production, value, market share and development plans in future.
  • Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
  • To define, describe and forecast the market by type, application and region.
  • To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
  • To identify significant trends and factors driving or inhibiting the market growth.
  • To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
  • To strategically analyze each submarket with respect to individual growth trend and their contribution to the market
  • To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
  • To strategically profile the key players and comprehensively analyze their growth strategies.

Daksh

Daksh is an SEO Analyst having 3 years of experienced. we can quickly understand and support initiatives that will contribute to the goals and success of client campaigns. and also Perform keyword research in coordination with client business objectives to optimize existing content and uncover new opportunities.

View all posts by Daksh →

Leave a Reply

Your email address will not be published. Required fields are marked *